Macrolides allergy

Current Pharmaceutical Design

Volumn 14, Issue 27, 2008, Pages 2840-2862

  Araújo, Luis ^a   Demoly, Pascal ^b  

^a UNIVERSITY OF PORTO   (Portugal)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Allergy; Diagnosis; Drug allergy macrolides

Indexed keywords

AZITHROMYCIN; CARBAMAZEPINE; CIMETIDINE; CLARITHROMYCIN; CYCLOSPORIN A; CYTOCHROME P450; DIGOXIN; ERYTHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; JOSAMYCIN; KETOLIDE; KITASAMYCIN; MACROLIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MIDAZOLAM; MIDECAMYCIN; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; RIFABUTIN; RIFAMPICIN; RITONAVIR; ROXITHROMYCIN; SPIRAMYCIN; TELITHROMYCIN; TERFENADINE; THEOPHYLLINE; TROLEANDOMYCIN;

ABDOMINAL CRAMP; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ACUTE SINUSITIS; ALLERGIC PNEUMONITIS; ANAPHYLACTIC SHOCK; ANAPHYLACTOID PURPURA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBIOTIC RESISTANCE; ANTIGEN PRESENTING CELL; ANTIMICROBIAL ACTIVITY; B LYMPHOCYTE; BACTERIAL INFECTION; BRONCHOSPASM; CHOLESTATIC HEPATITIS; CHURG STRAUSS SYNDROME; CONTACT DERMATITIS; COUGHING; DESENSITIZATION; DIARRHEA; DRESS SYNDROME; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSPNEA; ECZEMA; ENZYME INACTIVATION; EOSINOPHILIA; ERYTHEMA MULTIFORME; ERYTHEMATOPUSTULOSIS ERUPTION; EXFOLIATIVE DERMATITIS; GASTROINTESTINAL DISEASE; GENITAL ULCER; HEARING IMPAIRMENT; HELICOBACTER INFECTION; HEPATITIS; HUMAN; IMMUNOPATHOLOGY; INTERNATIONAL NORMALIZED RATIO; LARYNX EDEMA; LIVER FAILURE; LIVER NECROSIS; LIVER TOXICITY; LOEFFLER PNEUMONIA; LUNG INFILTRATE; LYMPHOCYTE TRANSFORMATION TEST; MACULOPAPULAR RASH; MYOPATHY; NAUSEA; NEUTROPENIA; NONHUMAN; OCCUPATIONAL ASTHMA; OTOTOXICITY; PATCH TEST; PELVIC INFLAMMATORY DISEASE; PERCEPTION DEAFNESS; PERIVASCULAR LYMPHOCYTIC DERMATITIS; PEROPERATIVE ANAPHYLAXIS; PRICK TEST; PRIORITY JOURNAL; PROTEIN INTERACTION; PROVOCATION TEST; PRURITUS; PURPURA; PUSTULOSIS; QT PROLONGATION; RED NECK SYNDROME; RESPIRATORY TRACT INFECTION; REVIEW; RHABDOMYOLYSIS; RHINITIS; RHINOCONJUNCTIVITIS; SERUM SICKNESS; SKIN INFECTION; SKIN TEST; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; THROMBOPHLEBITIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; URETHRITIS; URTICARIA; UTERINE CERVICITIS; VASCULITIS; VOMITING;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG HYPERSENSITIVITY; HUMANS; HYPERSENSITIVITY; MACROLIDES;

EID: 65949122532     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786369812     Document Type: Review

References (368)

1. Blondeau JM, De Carolis E, Metzler KL, Hansen GT. The macrolides. Expert Opin Investig Drugs 2002; 11: 189-215.
2. Whitman MS, Tunkel AR. Azithromycin and clarithromycin: Overview and comparison with erythromycin. Infect Control Hosp Epidemiol 1992; 13: 357-68.
3. Zuckerman JM, Kaye KM. The newer macrolides: Azithromycin and clarithromycin. Infect Dis Clin North Am1995; 9: 731-45.
4. Amsden GW. Erythromycin, clarithromycin, and azithromycin: Are the differences real? Clin Ther 1996; 18: 56-72.
5. McKenna S, Evans GA. Macrolides: A Canadian infectious disease society position paper. Can J Infect Dis 2001; 12: 218-31.
6. Zhanel GG, Dueck M, Hoban DJ, Vercaigne LM, Embil JM, Gin AS, et al. Review of macrolides and ketolides: Focus on respiratory tract infections. Drugs 2001; 61: 443-98.
7. Mazzei T, Mini E, Novelli A, Periti P. Chemistry and mode of action of macrolides. J Antimicrob Chemother 1993; 31: S1-9.
8. File TM. Telithromycin new product overview. J Allergy Clin Immunol 2005; 115: S1-13.
9. Peters DH, Friedel HA, McTavish D. Azithromycin: A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992; 44: 750-99.
10. Jain R, Danziger LH. The macrolide antibiotics: A pharmacokinetic and pharmacodynamic overview. Curr Pharm Des 2004; 10: 3045-53.
11. Schwab JC, Mandell GL. The importance of penetration of antimicrobial agents into cells. Infect Dis Clin North Am 1989; 3: 461-7.
12. Wreiber K, Olsson-Liljequist B, Engstrand L. Development of resistant Helicobacter pylori in Sweden. Tendency toward increasing resistance to clarithromycin. Lakartidningen 1999 10; 96: 582-4.
13. Williams JD, Sefton AM. Comparison of macrolide antibiotics. J Antimicrob Chemother 1993; 31: S11-26.
14. Amsden GW. Advanced-generation macrolides: Tissue-directed antibiotics. Int J Antimicrob Agents 2001; 18: S11-5.
15. Nightingale CH. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr Infect Dis J 1997; 16: 438-43.
16. Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents 2001;18: S71-6.
17. Polasek TM, Miners JO. Quantitative prediction of macrolide drugdrug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur J Clin Pharmacol 2006; 62: 203-8.
18. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23: 106-31.
19. Pessayre D, Tinel M, Larrey D, Cobert B, Funck-Brentano C, Babany G. Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione. J Pharmacol Exp Ther 1983; 224: 685-91.
20. Ito K, Ogihara K, Kanamitsu S, Itoh T. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 2003; 31: 945-54.
21. Zhong DF, Zhang SQ, Sun L, Zhao XY. Metabolism of roxithromycin in phenobarbital-treated rat liver microsomes. Acta Pharmacol Sin 2002; 23: 455-60.
22. Choudhury L, Grais IM, Passman RS. Torsades de pointes due to drug interaction between disopyramide and clarithromycin. Heart Dis 1999; 1: 206-7.
23. Takedomi S, Matsuo H, Yamano K, Ohtani H, Sawada Y. In-vivo kinetics of the interaction between midazolam and erythromycin in rats, taking account of metabolic intermediate complex formation. J Pharm Pharmacol 2001; 53: 643-51.
24. Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 2000; 17: 419-26.
25. Lee DO, Lee CD. Serotonin syndrome in a child associated with erythromycin and sertraline. Pharmacotherapy 1999; 19: 894-6.
26. von Rosensteil NA, Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 1995; 13: 105-22.
27. Lindstrom TD, Hanssen BR, Wrighton SA. Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrob Agents Chemother 1993; 37: 265-9.
28. Amacher DE, Schomaker SJ, Retsema JA. Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrob Agents Chemother 1991; 35: 1186-90.
29. Svensson CK, Drobitch RK, Kloss KA. Effect of glutathione depletion on the in vivo inhibition of drug metabolism by agents forming an inactive cytochrome P-450 Fe(II):mEtabolite complex. Studies with amiodarone and troleandomycin. J Pharm Sci 1991; 80: 225-8.
30. Villa P, Sassella D, Corada M, Bartosek I. Effects of roxithromycin, a new semisynthetic macrolide, and two erythromycins on drug metabolizing enzymes in rat liver. J Antibiot (Tokyo) 1988; 41: 563-9.
31. Larrey D, Tinel M, Pessayre D. Formation of inactive cytochrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats. Biochem Pharmacol 1983; 32: 1487-93.
32. Larrey D, Funck-Brentano C, Breil P, Vitaux J, Theodore C, Babany G, et al. Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem Pharmacol 1983; 32: 1063-8.
33. Pessayre D. Effects of macrolide antibiotics on drug metabolism in rats and in humans. Int J Clin Pharmacol Res 1983; 3: 449-58.
34. Pessayre D, Larrey D, Vitaux J, Breil P, Belghiti J, Benhamou JP. Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans. Biochem Pharmacol 1982; 31: 1699-704.
35. Danan G, Descatoire V, Pessayre D. Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. J Pharmacol Exp Ther 1981; 218: 509-14.
36. Yang KH, Lee JH, Lee MG. Effects of CYP inducers and inhibitors on the pharmacokinetics of intravenous theophylline in rats: Involvement of CYP1A1/2 in the formation of 1,3-DMU. J Pharm Pharmacol 2008; 60: 45-53.
37. Choi HD, Kang HE, Chung HJ, Bae SK, Shin KN, Lee MG. Effects of water deprivation on the pharmacokinetics of theophylline and one of its metabolites, 1,3-dimethyluric acid, after intravenous and oral administration of aminophylline to rats. Biopharm Drug Dispos 2007; 28: 445-54.
38. Matsunaga N, Hayashi M, Yamamoto K, Nishijima T, Kizu J, Nishihara K, et al. Simultaneous assessment of the in vivo amount of CYP1A2 and CYP3A2 by the PKCYP-test using theophylline in rats. Drug Metab Pharmacokinet 2002; 17: 190-8.
39. Tjia JF, Colbert J, Back DJ. Theophylline metabolism in human liver microsomes: Inhibition studies. J Pharmacol Exp Ther 1996; 276: 912-7
40. Lake KD. Management of drug interactions with cyclosporine. Pharmacotherapy 1991; 11: 110S-8S.
41. Henricsson S, Lindholm A, Aravoglou M. Cyclosporin metabolism in human liver microsomes and its inhibition by other drugs. Pharmacol Toxicol 1990; 66: 49-52.
42. Fabre I, Richard B, Combalbert J, Fabre G, Cano JP. The interaction between cyclosporin A and erythromycin studied by means of an isolated perfused rat liver model. Pharmacol Toxicol 1989;65:198-203.
43. Jones BC, Hyland R, Ackland M, Tyman CA, Smith DA. Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6. Drug Metab Dispos 1998; 26: 875-82.
44. Ling KH, Leeson GA, Burmaster SD, Hook RH, Reith MK, Cheng LK. Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metab Dispos 1995; 23: 631-6.
45. Luoma PV. Microsomal enzyme induction, lipoproteins and atherosclerosis. Pharmacol Toxicol 1988; 62: 243-9.
46. Gurevitz SL. Erythromycin: Drug interactions. J Dent Hyg 1997; 71: 159-61.
47. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41-57.
48. Hassan-Alin M, Andersson T, Niazi M, Liljeblad M, Persson BA, Rohss K. Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects. Int J Clin Pharmacol Ther 2006; 44: 119-27.
49. Calabresi L, Pazzucconi F, Ferrara S, Di Paolo A, Tacca MD, Sirtori C. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers. Pharmacol Res 2004; 49: 493-9.
50. Sekar VJ, Spinosa-Guzman S, De Paepe E, De Pauw M, Vangeneugden T, Lefebvre E, et al. Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers. J Clin Pharmacol 2008; 48: 60-5.
51. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin and rifabutin drug interactions. Am J Med Sci 2008; 335: 126-36.
52. Taki H, Ogawa K, Nakagawa T, Kashima K, Tarumi O, Saitou Y, et al. Clinical analysis of drug interaction between rifampicin and clarithromycin which are used for treating pulmonary Mycobacterium avium complex infection. Kekkaku 2007; 82: 641-6.
53. Pauwels O. Factors contributing to carbamazepine-macrolide interactions. Pharmacol Res 2002;45:291-8.
54. Yasui N, Otani K, Kaneko S, Shimoyama R, Ohkubo T, Sugawara K. Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients. Int Clin Psychopharmacol 1997; 12: 225-9.
55. Amsden GW, Cheng KL, Peloquin CA, Nafziger AN. Oral cimetidine prolongs clarithromycin absorption. Antimicrob Agents Chemother 1998; 42: 1578-80.
56. Quinney SK, Haehner BD, Rhoades MB, Lin Z, Gorski JC, Hall SD. Interaction between midazolam and clarithromycin in the elderly. Br J Clin Pharmacol 2008; 65: 98-109.
57. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM, Jr., Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998; 64: 133-43.
58. Yeates RA, Laufen H, Zimmermann T, Schumacher T. Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin, clarithromycin, and the azalide azithromycin. Int J Clin Pharmacol Ther 1997; 35: 577-9.
59. Yeates RA, Laufen H, Zimmermann T. Interaction between midazolam and clarithromycin: Comparison with azithromycin. Int J Clin Pharmacol Ther 1996; 34: 400-5.
60. Goss JE, Ramo BW, Blake K. Torsades de pointes associated with astemizole (Hismanal) therapy. Arch Intern Med 1993 13; 153: 2705.
61. Sadaba B, Lopez de Ocariz A, Azanza JR, Quiroga J, Cienfuegos JA. Concurrent clarithromycin and cyclosporin A treatment. J Antimicrob Chemother 1998; 42: 393-5.
62. Spicer ST, Liddle C, Chapman JR, Barclay P, Nankivell BJ, Thomas P, et al. The mechanism of cyclosporine toxicity induced by clarithromycin. Br J Clin Pharmacol 1997; 43: 194-6.
63. Gomez E, Sanchez JE, Aguado S, Alvarez Grande J. Interaction between azithromycin and cyclosporin? Nephron 1996; 73: 724.
64. Page RL, 2nd, Ruscin JM, Fish D, Lapointe M. Possible interaction between intravenous azithromycin and oral cyclosporine. Pharmacotherapy 2001; 21: 1436-43.
65. Ljutic D, Rumboldt Z. Possible interaction between azithromycin and cyclosporin: A case report. Nephron 1995; 70: 130.
66. Trivedi S, Hyman J, Lichstein E. Clarithromycin and digoxin toxicity. Ann Intern Med 1998; 128: 604.
67. Bizjak ED, Mauro VF. Digoxin-macrolide drug interaction. Ann Pharmacother 1997; 31: 1077-9.
68. Corallo CE, Rogers IR. Roxithromycin-induced digoxin toxicity. Med J Aust 1996; 165: 433-4.
69. Morton MR, Cooper JW. Erythromycin-induced digoxin toxicity. Dicp 1989; 23: 668-70.
70. Sutton A, Pilot MA. Digoxin toxicity and erythromycin. Bmj 1989; 298: 1101.
71. Tanaka H, Matsumoto K, Ueno K, Kodama M, Yoneda K, Katayama Y, et al. Effect of clarithromycin on steady-state digoxin concentrations. Ann Pharmacother 2003; 37: 178-81.
72. Tsutsumi K, Kotegawa T, Kuranari M, Otani Y, Morimoto T, Matsuki S, et al. The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers. J Clin Pharmacol 2002; 42: 1159-64.
73. Nenciu LM, Laberge P, Thirion DJ. Telithromycin-induced digoxin toxicity and electrocardiographic changes. Pharmacotherapy 2006; 26: 872-6.
74. Hirata S, Izumi S, Furukubo T, Ota M, Fujita M, Yamakawa T, et al. Interactions between clarithromycin and digoxin in patients with end-stage renal disease. Int J Clin Pharmacol Ther 2005; 43: 30-6.
75. Campbell G, Jayakumar U, McCracken S, Bene J. A cautionary tale: Delayed onset rhabdomyolysis due to erythromycin/simvastatin interaction. Age Ageing 2007; 36: 597.
76. Chouhan UM, Chakrabarti S, Millward LJ. Simvastatin interaction with clarithromycin and amiodarone causing myositis. Ann Pharmacother 2005; 39: 1760-1.
77. Piacentini N, Trifiro G, Tari M, Moretti S, Arcoraci V. Statinmacrolide interaction risk: A population-based study throughout a general practice database. Eur J Clin Pharmacol 2005; 61: 615-20.
78. Morera T, Gervasini G, Carrillo JA, Benitez J. Evaluation of a drug-drug interaction alert structure through the retrospective analysis of statins-macrolides co-prescriptions. Basic Clin Pharmacol Toxicol 2005; 96: 289-94.
79. Trieu J, Emmett L, Perera C, Thanakrishnan K, Van Der Wall H. Rhabdomyolysis resulting from interaction of simvastatin and clarithromycin demonstrated by Tc-99m MDP scintigraphy. Clin Nucl Med 2004; 29: 803-4.
80. Kahri AJ, Valkonen MM, Vuoristo MK, Pentikainen PJ. Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin. Ann Pharmacother 2004; 38: 719.
81. Amsden GW, Kuye O, Wei GC. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Clin Pharmacol 2002; 42: 444-9.
82. Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001; 35: 26-31.
83. Siedlik PH, Olson SC, Yang BB, Stern RH. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol 1999; 39: 501-4.
84. Wong PW, Dillard TA, Kroenke K. Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy. South Med J 1998; 91: 202-5.
85. Amsden G, Flaherty J, Luke D. Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients. J Clin Pharmacol 2001; 41: 210-6.
86. Boruchoff SE, Sturgill MG, Grasing KW, Seibold JR, McCrea J, Winchell GA, et al. The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin. Clin Pharmacol Ther 2000; 67: 351-9.
87. Brophy DF, Israel DS, Pastor A, Gillotin C, Chittick GE, Symonds WT, et al. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. Antimicrob Agents Chemother 2000; 44: 978-84.
88. Ouellet D, Hsu A, Granneman GR, Carlson G, Cavanaugh J, Guenther H, et al. Pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther 1998; 64: 355-62.
89. Warning against using erythromycin (even orally) while using protease inhibitors or certain other drugs. AIDS Treat News 2004: 6.
90. Hafner R, Bethel J, Standiford HC, Follansbee S, Cohn DL, Polk RE, et al. Tolerance and pharmacokinetic interactions of rifabutin and azithromycin. Antimicrob Agents Chemother 2001; 45: 1572-7.
91. Kuper JI, D'Aprile M. Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet 2000; 39: 203-14.
92. Apseloff G, Foulds G, LaBoy-Goral L, Willavize S, Vincent J. Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers. J Clin Pharmacol 1998; 38: 830-5.
93. Hafner R, Bethel J, Power M, Landry B, Banach M, Mole L, et al. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob Agents Chemother 1998; 42: 631-9.
94. Iatsimirskaia E, Tulebaev S, Storozhuk E, Utkin I, Smith D, Gerber N, et al. Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin Pharmacol Ther 1997; 61: 554-62.
95. Griffith DE, Brown BA, Girard WM, Wallace RJ, Jr. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995;21:594-8.
96. Flockhart DA, Drici MD, Kerbusch T, Soukhova N, Richard E, Pearle PL, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 2000; 20: 317-24.
97. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095-106.
98. Shrader SP, Fermo JD, Dzikowski AL. Azithromycin and warfarin interaction. Pharmacotherapy 2004; 24: 945-9.
99. Kolilekas L, Anagnostopoulos GK, Lampaditis I, Eleftheriadis I. Potential interaction between telithromycin and warfarin. Ann Pharmacother 2004; 38: 1424-7.
100. Rao KB, Pallaki M, Tolbert SR, Hornick TR. Enhanced hypoprothrombinemia with warfarin due to azithromycin. Ann Pharmacother 2004; 38: 982-5.
101. Dandekar SS, Laidlaw DA. Suprachoroidal haemorrhage after addition of clarithromycin to warfarin. J R Soc Med 2001; 94: 583-4.
102. Beckey NP, Parra D, Colon A. Retrospective evaluation of a potential interaction between azithromycine and warfarin in patients stabilized on warfarin. Pharmacotherapy 2000; 20: 1055-9.
103. Recker MW, Kier KL. Potential interaction between clarithromycin and warfarin. Ann Pharmacother 1997; 31: 996-8.
104. Champney WS, Burdine R. Macrolide antibiotics inhibit 50S ribosomal subunit assembly in Bacillus subtilis and Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 2141-4.
105. Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: New macrolide antibiotics. Clin Pharm 1992; 11: 137-52.
106. Brisson-Noel A, Trieu-Cuot P, Courvalin P. Mechanism of action of spiramycin and other macrolides. J Antimicrob Chemother 1988; 22: S13-23.
107. Menninger JR. Functional consequences of binding macrolides to ribosomes. J Antimicrob Chemother 1985; 16: S23-34.
108. Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrobial Agents and Chemotherapy 1987; 31: 1939-47.
109. Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernandes PB. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrobial Agents and Chemotherapy 1988; 32: 1710-9.
110. Fernandes PB, Hardy DJ. Comparative in vitro potencies of nine new macrolides. Drugs under Experimental and Clinical Research 1988; 14: 445-51.
111. Bryskier A. New research in macrolides and ketolides since 1997. Expert Opin Investig Drugs 1999; 8: 1171-94.
112. Zhanel GG, Walters M, Noreddin A, Vercaigne LM, Wierzbowski A, Embil JM, et al. The ketolides: A critical review. Drugs 2002; 62: 1771-804.
113. Foster TJ. Plasmid-determined resistance to antimicrobial drugs and toxic metal ions in bacteria. Microbiological Reviews 1983; 47: 361-409.
114. Fernandes PB, Baker WR, Freiberg LA, Hardy DJ, McDonald EJ. New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. Antimicrobial Agents and Chemotherapy 1989; 33: 78-81.
115. Carbon C, Poole MD. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. J Chemother 1999; 11: 107-18.
116. Felmingham D, Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens - Findings of the Alexander Project 1992-1996. J Chemother 1999; 11: S5-21.
117. International drug monitoring: The role of national centres. Report of a WHO meeting. World Health Organization - Technical Report Series 1972; 498: 1-25.
118. Principi N, Esposito S. Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Saf 1999; 20: 25-41.
119. Treadway G, Pontani D. Paediatric safety of azithromycin: Worldwide experience. J Antimicrob Chemother 1996; 37: S143-9.
120. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991;91:40S-5S.
121. Weippl G. Multicentre comparison of azithromycin versus erythromycin in the treatment of paediatric pharyngitis or tonsillitis caused by group A streptococci. J Antimicrob Chemother 1993; 31: S95-101.
122. Roord JJ, Wolf BH, Gossens MM, Kimpen JL. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections. Antimicrob Agents Chemother 1996; 40: 2765-8.
123. Block S, Hedrick J, Hammerschlag MR, Cassell GH, Craft JC. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: Comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J 1995; 14: 471-7.
124. Arguedas A, Loaiza C, Rodriguez F, Herrera ML, Mohs E. Comparative trial of 3 days of azithromycin versus 10 days of clarithromycin in the treatment of children with acute otitis media with effusion. J Chemother 1997; 9: 44-50.
125. Zara GP, Qin XY, Pilot MA, Thomson HH, Maskell JP. Erythromycin and gastrointestinal motility. Lancet 1987; 2: 1036.
126. Peeters T, Matthijs G, Depoortere I, Cachet T, Hoogmartens J, Vantrappen G. Erythromycin is a motilin receptor agonist. Am J Physiol 1989; 257: G470-4.
127. Sarna SK, Soergel KH, Koch TR, Stone JE, Wood CM, Ryan RP, et al. Gastrointestinal motor effects of erythromycin in humans. Gastroenterology 1991; 101: 1488-96.
128. Periti P, Mazzei T, Mini E, Novelli A. Adverse effects of macrolide antibacterials. Drug Saf 1993; 9: 346-64.
129. Marlin GE, Thompson PJ, Jenkins CR, Burgess KR, LaFranier DA. Study of serum levels, venous irritation and gastrointestinal side-effects with intravenous erythromycin lactobionate in patients with bronchopulmonary infection. Hum Toxicol 1983; 2: 593-605.
130. Sacristan JA, Soto J. Erythromycin ototoxicity: Methodology and conclusions. Am J Med 1993; 94: 227-9.
131. Haydon RC, Thelin JW, Davis WE. Erythromycin ototoxicity: Analysis and conclusions based on 22 case reports. Otolaryngol Head Neck Surg 1984; 92: 678-84.
132. Uzun C, Koten M, Adali MK, Yorulmaz F, Yagiz R, Karasalihoglu AR. Reversible ototoxic effect of azithromycin and clarithromycin on transiently evoked otoacoustic emissions in guinea pigs. J Laryngol Otol 2001; 115: 622-8.
133. Mamikoglu B, Mamikoglu O. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report. Ann Otol Rhinol Laryngol 2001; 110:102.
134. Ress BD, Gross EM. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report. Ann Otol Rhinol Laryngol 2000; 109: 435-7.
135. Bizjak ED, Haug MT, 3rd, Schilz RJ, Sarodia BD, Dresing JM. Intravenous azithromycin-induced ototoxicity. Pharmacotherapy 1999; 19: 245-8.
136. Wallace MR, Miller LK, Nguyen MT, Shields AR. Ototoxicity with azithromycin. Lancet 1994; 343: 241.
137. Domenech J, Cuchi MA, Fuste J, Traserra Coderch J. Evaluation of the possible ototoxicity of josamycin by high frequency audiometry. An Otorrinolaringol Ibero Am 1993; 20: 173-8.
138. Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113: 832-6.
139. Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005; 5: 309-16.
140. Johansson SGO, Hourihane JOB, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 56: 813-24.
141. Pichler WJ. Delayed Drug Hypersensitivity Reactions. Ann Intern Med 2003; 139: 683-93.
142. Demoly P, Bousquet J. Epidemiology of drug allergy. Curr Opin Allergy Clin Immunol 2001; 1: 305-10.
143. Guglielmi L, Guglielmi P, Demoly P. Drug hypersensitivity: Epidemiology and risk factors. Curr Pharm Design 2006; 12: 3309-12.
144. Matzinger P. Tolerance, danger, and the extended family. Ann Rev Immunol 1994; 12: 991-1045.
145. Séguin B, Uetrecht J. The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol 2003; 3: 235-42.
146. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: The p-i concept. Curr Opin Allergy Clin Immunol 2002; 2: 301-5.
147. Demoly P, Kropf R, Bircher A, Pichler WJ. Drug hypersensitivity: Questionnaire. Allergy Euro 1999; 54: 999-1003.
148. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57: 45-51.
149. Barbaud A, Reichert-Penetrat S, Tréchot P, Jacquin-Petit MA, Ehlinger A, Noirez V, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 1998; 139: 49-58.
150. DeLeo VA. Skin testing in systemic cutaneous drug reactions. Lancet 1998; 352: 1488-90.
151. Calkin JM, Maibach HI. Delayed hypersensitivity drug reactions diagnosed by patch testing. Contact Dermatitis 1993; 29: 223-33.
152. Bruynzeel DP, Maibach HI. Patch testing in systemic drug eruptions. Clin Dermatol 1997; 15: 479-84.
153. Osawa J, Naito S, Aihara M, Kitamura K, Ikezawa Z, Nakajima H. Evaluation of skin test reactions in patients with non-immediate type drug eruptions. J Dermatol 1990; 17: 235-9.
154. Schnyder B, Helbling A, Kappeler A, Pichler WJ. Drug-induced papulovesicular exanthema. Allergy 1998; 53: 817-8.
155. Blanca M, Vega JM, Garcia J, Carmona MJ, Terados S, Avila MJ, et al. Allergy to penicillin with good tolerance to other penicillins; study of the incidence in subjects allergic to betalactams. Clin Exp Allergy 1990; 20: 475-81.
156. Pascual C, Crespo JF, Quiralte J, Lopez C, Wheeler G, Martin-Esteban M. In vitro detection of specific IgE antibodies to erythromycin. J Allergy Clin Immunol 1995; 95: 668-71.
157. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004; 59: 809-20.
158. Cooksley WG, Powell LW. Erythromycin jaundice: Diagnosis by an in vitro challenge test. Aust N Z J Med 1977; 7: 291-3.
159. Goossens C, Sass U, Song M. Baboon syndrome. Dermatology 1997; 194: 421-2.
160. Ohnishi H, Abe M, Yokoyama A, Hamada H, Ito R, Hirayama T, et al. Clarithromycin-induced eosinophilic pneumonia. Intern Med 2004; 43: 231-5.
161. Lopez Serrano C, Quiralte Enriquez J, Martinez Alzamora F. Urticaria from erythromycin. Allergol Immunopathol (Madr) 1993; 21: 225-6.
162. Igea JM, Quirce S, de la Hoz B, Fraj J, Pola J, Diez Gomez ML. Adverse cutaneous reactions due to macrolides. Ann Allergy 1991; 66: 216-8.
163. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: General considerations. Allergy 2003; 58: 854-63.
164. Li WPA, Kendall MJ. Causality assessment of adverse effects when is re-challenge ethically acceptable? Drug Safety 2001; 24: 793-9.
165. Casadevall J, Ventura PJ, Mullol J, Picado C. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: Evaluation of nasal response by acoustic rhinometry. Thorax 2000; 55: 921-4.
166. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczynska M, Picado C, Scadding G, et al. EAACI/GA2LEN guideline: Aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007; 62: 1111-8.
167. Makowska JS, Grzegorczyk J, Bienkiewicz B, Wozniak M, Kowalski ML. Systemic responses after bronchial aspirin challenge in sensitive patients with asthma. J Allergy Clin Immunol 2008; 121: 348-54.
168. Friedlaender MH. Conjunctival provocation testing: Overview of recent clinical trials in ocular allergy. Curr Opin Allergy Clin Immunol 2002; 2: 413-7.
169. Fauquert JL, Mortemousque B, Bre?mond-Gignac D, Creuzot- Garcher C, Helleboid L, Chiambaretta F, et al. Conjunctival allergen challenge: Practical recommendations for the diagnosis of allergic conjunctivitis. Report (proceedings) of the meeting of the Group Ophthalmo Allergo (Journees parisiennes d'allergie, January 10, 2004). Le Test de provocation conjonctivale allergénique: Recommandations pratiques pour le diagnostic des conjonctivites allergiques Compte-rendu de la table ronde du Groupe Ophtalmo Allergo (GOA) Rev fr Allergol Clin Immunol 2004; 44: 689-99.
170. Hannuksela M, Salo H. The repeated open application test (ROAT). Contact Dermatitis 1986; 14: 221-7.
171. Reidenberg MM, Lowenthal DT. Adverse nondrug reactions. N Engl J Med 1968; 279: 678-9.
172. Bernstein IL, Gruchalla RS, Lee RE, Nicklas RA, Dykewicz MS. Disease management of drug hypersensitivity: A practice parameter: Preface. Ann Allergy, Asthma Immunol 1999; 83.
173. Idsoe O, Guthe T, Willcox RR, de Weck AL. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. Bulletin of the World Health Organization 1968; 38: 159-88.
174. Drain KL, Volcheck GW. Preventing and managing drug-induced anaphylaxis. Drug Safety 2001;24:843-53.
175. Lammintausta K, Kortekangas-Savolainen O. Oral challenge in patients with suspected cutaneous adverse drug reactions: Findings in 784 patients during a 25-year-period. Acta Dermato-Venereologica 2005; 85: 491-6.
176. Benahmed S, Scaramuzza C, Messaad D, Sahla H, Demoly P. The accuracy of the diagnosis of suspected macrolide antibiotic hypersensitivity: results of a single-blinded trial. Allergy 2004; 59: 1130-3.
177. Mahboob A, Haroon TS. Drugs causing fixed eruptions: A study of 450 cases. Int J Dermatol 1998; 37: 833-8.
178. Riley L, Mudd L, Baize T, Herzig R. Cross-sensitivity reaction between tacrolimus and macrolide antibiotics. Bone Marrow Transplant 2000; 25: 907-8.
179. Gruchalla RS. Acute drug desensitization. Clin Exp Allergy 1998;28:S63-4.
180. Gruchalla RS. 10. Drug allergy. J Allergy Clin Immunol 2003; 2: S111.
181. Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 2006; 6: 476-81.
182. Nucera E, Roncallo C, Masini L, Buonomo A, De Pasquale T, Pollastrini E, et al. Successful tolerance induction to spiramycin in pregnancy. Scand J Infect Dis 2002; 34: 550-1.
183. Matheu V, Franco A, Perez E, Hernandez M, Barrios Y. Omalizumab for drug allergy. J Allergy Clin Immunol 2007; 120: 1471-2.
184. Niederman MS, Bass Jr JB, Campbell GD, Fein AM, Grossman RF, Mandell LA, et al. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418-26
185. Stahl JE, Barza M, Desjardin J, Martin R, Eckman MH. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159: 2576-80.
186. Lode HM. Managing community-acquired pneumonia: A European perspective. Respir Med 2007; 101: 1864-73.
187. Malek E, Lebecque P. [Etology and treatment of community acquired pneumonia in children]. J Pharm Belg 2007; 62: 21-4.
188. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. Chest 2007; 131: 466-73.
189. Roig J, Casal J, Gispert P, Gea E. 13-Antibiotic therapy of community- acquired pneumonia (CAP) caused by atypical agents. Med Mal Infect 2006; 36: 680-9.
190. Lutfiyya MN, Henley E, Chang LF, Reyburn SW. Diagnosis and treatment of community-acquired pneumonia. Am Fam Physician 2006; 73: 442-50.
191. Carbon C, van Rensburg D, Hagberg L, Fogarty C, Tellier G, Rangaraju M, et al. Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia. Respir Med 2006; 100: 577-85.
192. van Rensburg D, Fogarty C, De Salvo MC, Rangaraju M, Nusrat R. Efficacy of oral telithromycin in community-acquired pneumonia caused by resistant Streptococcus pneumoniae. J Infect 2005; 51: 201-5.
193. British Thoracic Society Guidelines for the Management of Community Acquired Pneumonia in Childhood. Thorax 2002; 57: S1-24.
194. Mandell LA, Bartlett JG, Dowell SF, File TM, Jr., Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-33.
195. Dark D. Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infections. Am J Med 1991; 91: 31S-5S.
196. Blasi F, Cazzola M, Tarsia P, Cosentini R, Aliberti S, Santus P, et al. Azithromycin and lower respiratory tract infections. Expert Opin Pharmacother 2005; 6: 2335-51.
197. Panpanich R, Lerttrakarnnon P, Laopaiboon M. Azithromycin for acute lower respiratory tract infections. Cochrane Database Syst Rev 2004(4): CD001954.
198. Galvez-Mugica MA, Espinosa de los Monteros MJ, Gallego Sandin S, Novalbos J, Abad-Santos F. [Meta-analysis of clarithromycin compared to other antibiotics for the treatment of lower respiratory tract infections]. Rev Esp Quimioter 2003; 16: 403-11.
199. Contopoulos-Ioannidis DG, Ioannidis JP, Chew P, Lau J. Metaanalysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 2001;48:691-703.
200. Anzueto A, Niederman MS, Tillotson GS. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group. Clin Ther 1998; 20: 885-900.
201. Dimopoulos G, Siempos, II, Korbila IP, Manta KG, Falagas ME. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: A metaanalysis of randomized controlled trials. Chest 2007; 132: 447-55.
202. Niederman MS, Anzueto A, Sethi S, Choudhri S, Kureishi A, Haverstock D, et al. Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents. Respir Med 2006; 100: 1781-90.
203. Blasi F, Ewig S, Torres A, Huchon G. A review of guidelines for antibacterial use in acute exacerbations of chronic bronchitis. Pulm Pharmacol Ther 2006; 19: 361-9.
204. Swainston Harrison T, Keam SJ. Azithromycin extended release: A review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US. Drugs 2007; 67: 773-92.
205. Margaritis VK, Ismailos GS, Naxakis SS, Mastronikolis NS, Goumas PD. Sinus fluid penetration of oral clarithromycin and azithromycin in patients with acute rhinosinusitis. Am J Rhinol 2007; 21: 574-8.
206. Alagic-Smailbegovic J, Saracevic E, Sutalo K. Azythromicin versus amoxicillin-clavulanate in the treatment of acute sinusitis in children. Bosn J Basic Med Sci 2006; 6: 76-8.
207. Tellier G, Brunton SA, Nusrat R. Telithromycin for the treatment of acute bacterial maxillary sinusitis: A review of a new antibacterial agent. South Med J 2005; 98: 863-8.
208. Dubreuil C, Ebbo D, Goldstein F. [Efficacy and safety of telithromycin in the treatment of acute maxillary sinusitis]. Med Mal Infect 2005; 35: 197-204.
209. Rechtweg JS, Moinuddin R, Houser SM, Mamikoglu B, Corey JP. Quality of life in treatment of acute rhinosinusitis with clarithromycin and amoxicillin/clavulanate. Laryngoscope 2004; 114: 806-10.
210. Hassmann-Poznanska E, Skotnicka B, Baczek M. [Efficacy of clarithromycin (Fromilid) in treatment of uncomplicated acute bacterial rhinosinusitis in children]. Otolaryngol Pol 2003; 57: 829-33.
211. Klapan I, Culig J, Oreskovic K, Matrapazovski M, Radosevic S. Azithromycin versus amoxicillin/clavulanate in the treatment of acute sinusitis. Am J Otolaryngol 1999; 20: 7-11.
212. Clifford K, Huck W, Shan M, Tosiello R, Echols RM, Heyd A. Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group. Ann Otol Rhinol Laryngol 1999; 108: 360-7.
213. Karpov OI, Riabova MA, Karpishchenko SA, Zaitseva AA. [Comparative trial of 3-day azithromycin versus 10-day coamoxilav course efficacy in acute sinusitis]. Ter Arkh 1998; 70: 72-6.
214. Clement PA, de Gandt JB. A comparison of the efficacy, tolerability and safety of azithromycin and co-amoxiclav in the treatment of sinusitis in adults. J Int Med Res 1998; 26: 66-75.
215. Chatzimanolis E, Marsan N, Lefatzis D, Pavlopoulos A. Comparison of roxithromycin with co-amoxiclav in patients with sinusitis. J Antimicrob Chemother 1998; 41: S81-4.
216. Dubois J, Saint-Pierre C, Tremblay C. Efficacy of clarithromycin vs. amoxicillin/clavulanate in the treatment of acute maxillary sinusitis. Ear Nose Throat J 1993; 72: 804-10.
217. Calhoun KH, Hokanson JA. Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis. Arch Fam Med 1993; 2: 837-40.
218. Karma P, Pukander J, Penttila M, Ylikoski J, Savolainen S, Olen L, et al. The comparative efficacy and safety of clarithromycin and amoxycillin in the treatment of outpatients with acute maxillary sinusitis. J Antimicrob Chemother 1991; 27: S83-90.
219. Casiano RR. Azithromycin and amoxicillin in the treatment of acute maxillary sinusitis. Am J Med 1991; 91: S27-30.
220. Cohen R, Reinert P, De La Rocque F, Levy C, Boucherat M, Robert M, et al. Comparison of two dosages of azithromycin for three days versus penicillin V for ten days in acute group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J 2002; 21: 297-303.
221. Cremer J, Wallrauch C, Milatovic D, Braveny I. Azithromycin versus cefaclor in the treatment of pediatric patients with acute group A beta-hemolytic streptococcal tonsillopharyngitis. Eur J Clin Microbiol Infect Dis 1998; 17: 235-9.
222. Hooton TM. A comparison of azithromycin and penicillin V for the treatment of streptococcal pharyngitis. Am J Med 1991; 91: S-6-23.
223. Dunne MW, Latiolais T, Lewis B, Pistorius B, Bottenfield G, Moore WH, et al. Randomized, double-blind study of the clinical efficacy of 3 days of azithromycin compared with co-amoxiclav for the treatment of acute otitis media. J Antimicrob Chemother 2003; 52: 469-72.
224. Mira E, Benazzo M. A multicenter study on the clinical efficacy and safety of roxithromycin in the treatment of ear-nose-throat infections: comparison with amoxycillin/clavulanic acid. J Chemother 2001; 13: 621-7.
225. Devereux RB, Frary CJ, Kramer-Fox R, Roberts RB, Ruchlin HS. Cost-effectiveness of infective endocarditis prophylaxis for mitral valve prolapse with or without a mitral regurgitant murmur. Am J Cardiol 1994; 74: 1024-9.
226. Pankuch GA, Lin G, Appelbaum PC. Activity of five quinolones, three macrolides and telithromycin against 12 Haemophilus influenzae strains with different resistance phenotypes. Clin Microbiol Infect 2005; 11: 1040-4.
227. Kosowska K, Credito K, Pankuch GA, Hoellman D, Lin G, Clark C, et al. Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae. Antimicrob Agents Chemother 2004; 48: 4113-9.
228. Brown SD, Rybak MJ. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study. J Antimicrob Chemother 2004; 54: I7-15.
229. Bergamaschi A, Magrini A, Pietroiusti A. Recent Advances in the Treatment of Helicobacter pylori Infection. Recent Patents Anti- Infect Drug Disc 2007; 2: 197-205.
230. Moayyedi P. Sequential regimens for Helicobacter pylori eradication. Lancet 2007; 370: 1010-2.
231. Mahachai V, Thong-Ngam D, Noophun P, Tumwasorn S, Kullavanijaya P. Efficacy of clarithromycin-based triple therapy for treating Helicobacter pylori in Thai non-ulcer dyspeptic patients with clarithromycin-resistant strains. J Med Assoc Thai 2006; 89: S74-8.
232. Ishioka H, Mizuno M, Take S, Ishiki K, Nagahara Y, Yoshida T, et al. A better cure rate with 800 mg than with 400 mg clarithromycin regimens in one-week triple therapy for Helicobacter pylori infection in cigarette-smoking peptic ulcer patients. Digestion 2007;75:63-8.
233. Paoluzi P, Iacopini F, Crispino P, Nardi F, Bella A, Rivera M, et al. 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: A large prospective single-center randomized study. Helicobacter 2006; 11: 562-8.
234. Ballard RC, Ye H, Matta A, Dangor Y, Radebe F. Treatment of chancroid with azithromycin. Int J STD AIDS 1996;7:S9-12.
235. Kimani J, Bwayo JJ, Anzala AO, MacLean I, Mwatha A, Choudri SH, et al. Low dose erythromycin regimen for the treatment of chancroid. East Afr Med J 1995; 72: 645-8.
236. Lewis DA. Chancroid: Clinical manifestations, diagnosis, and management. Sex Transm Infect 2003; 79: 68-71.
237. National guideline for the management of lymphogranuloma venereum. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect 1999; 75: S40-2.
238. Martin DH, Mroczkowski TF, Dalu ZA, McCarty J, Jones RB, Hopkins SJ, et al. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group. N Engl J Med 1992; 327: 921-5.
239. Linnemann CC, Jr., Heaton CL, Ritchey M. Treatment of Chlamydia trachomatis infections: Comparison of 1- and 2-g doses of erythromycin daily for seven days. Sex Transm Dis 1987; 14: 102-
240. Bitsouni E, Iavazzo C, Athanasiou S, Falagas ME. Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: A meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2007; 30: 213-21.
241. Geisler WM. Management of uncomplicated Chlamydia trachomatis infections in adolescents and adults: Evidence reviewed for the 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis 2007; 44: S77-83.
242. Martinot M. [Microbiological and pharmacological data useful for the treatment of Lyme disease. Treatment and follow up of early Lyme disease (erythema migrans)]. Med Mal Infect 2007; 37: 394-409.
243. Hunfeld KP, Wichelhaus TA, Rodel R, Acker G, Brade V, Kraiczy P. Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother 2004; 48: 344-7.
244. Donta ST. Macrolide therapy of chronic Lyme Disease. Med Sci Monit 2003; 9: PI136-42.
245. Barsic B, Maretic T, Majerus L, Strugar J. Comparison of azithromycin and doxycycline in the treatment of erythema migrans. Infection 2000; 28: 153-6.
246. Loewen PS, Marra CA, Marra F. Systematic review of the treatment of early Lyme disease. Drugs 1999; 57: 157-73.
247. Freund YR, Dousman L, Mohagheghpour N. Prophylactic clarithromycin to treat mycobacterium avium in HIV patients receiving zidovudine may significantly increase mortality by suppressing lymphopoiesis and hematopoiesis. Int Immunopharmacol 2002; 2: 1465-75.
248. Phillips P, Chan K, Hogg R, Bessuille E, Black W, Talbot J, et al. Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: Evaluation of a provincial program. Clin Infect Dis 2002; 34: 371-8.
249. Azithro once a week for MAC. TreatmentUpdate 1998; 10: 3-4.
250. Benson CA, Williams PL, Cohn DL, Becker S, Hojczyk P, Nevin T, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis 2000; 181: 1289-97.
251. Sendi PP, Craig BA, Meier G, Pfluger D, Gafni A, Opravil M, et al. Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study. J Antimicrob Chemother 1999; 44: 811-7.
252. Hewitt RG, Papandonatos GD, Shelton MJ, Hsiao CB, Harmon BJ, Kaczmarek SR, et al. Prevention of disseminated Mycobacterium avium complex infection with reduced dose clarithromycin in patients with advanced HIV disease. Aids 1999; 13: 1367-72.
253. Kobashi Y, Matsushima T. The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan - including a follow-up study. Respiration 2007; 74: 394-400.
254. Fujikane T, Fujiuchi S, Yamazaki Y, Sato M, Yamamoto Y, Takeda A, et al. Efficacy and outcomes of clarithromycin treatment for pulmonary MAC disease. Int J Tuberc Lung Dis 2005; 9: 1281- 7.
255. Bermudez LE, Yamazaki Y. Effects of macrolides and ketolides on mycobacterial infections. Curr Pharm Des 2004; 10: 3221-8.
256. Richeldi L, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG. Macrolides for chronic asthma. Cochrane Database Syst Rev 2005(4): CD002997.
257. Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2004(2): CD002203.
258. Oda H, Kadota JI, Kohno S, Hara K. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. Chest 1994; 106: 1116-23.
259. Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 1994; 49: 531-2.
260. Polat M, Lenk N, Yalcin B, Gur G, Tamer E, Artuz F, et al. Efficacy of erythromycin for psoriasis vulgaris. Clin Exp Dermatol 2007; 32: 295-7.
261. Kamada MM, Twarog F, Leung DYM. Multiple antibiotic sensitivity in a pediatric population. Allergy Proceedings 1991; 12: 347-50.
262. Martin J, Abbott GD. Serum sickness like illness and antimicrobials in children. N Z Med J 1995; 108: 123-4.
263. Van Der Linden PD, Van Der Lei J, Vlug AE, Stricker BHC. Skin reactions to antibacterial agents in general practice. J Clin Epidemiol 1998; 51: 703-8.
264. Wessel F. Per-anaesthetic allergy to antibiotics. Les allergies peranesthesiques aux antibiotiques 1998; 30: 190-2.
265. Mahboob A, Haroon TS. Drugs causing fixed eruptions: A study of 450 cases. Intern J Dermatol 1998; 37: 833-8.
266. Naldi L, Conforti A, Venegoni M, Troncon MG, Caputi A, Ghiotto E, et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999; 48: 839- 46.
267. Park J, Matsui D, Rieder MJ. Multiple antibiotic sensitivity syndrome in children. Can J Clin Pharmacol 2000; 7: 38-41.
268. Sharma VK, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: Clinical pattern and causative agents - A 6 year series from chandigarh, India. J Postgrad Med 2001; 47: 95-9.
269. Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: A review of 10 years' experience. Drug Safety 2002; 25: 965-72.
270. Saissi EH, Beau-Salinas F, Jonville-Bera AP, Lorette G, Autret-Leca E. Drugs associated with acute generalized exanthematic pustulosis. Médicaments associés à la survenue d'une pustulose exanthematique aiguë généralisée 2003; 130: 612-8.
271. Noel MV, Sushma M, Guido S. Cutaneous adverse drug reactions in hospitalized patients in a tertiary care center. Indian J Pharmacol 2004; 36: 292-5.
272. Messaad D, Sahla H, Benahmed S, Godard P, Bousquet J, Demoly P. Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann Intern Med 2004; 140: 1001-6.
273. Rallis E, Balatsouras DG, Kouskoukis C, Verros C, Homsioglou E. Drug eruptions in children with ENT infections. Int J Pediatr Otorhinolaryngol 2006; 70: 53-7.
274. Dore J, Salisbury RE. Morbidity and mortality of mucocutaneous diseases in the pediatric population at a tertiary care center. J Burn Care Res 2007; 28: 865-70.
275. Lange L, Koningsbruggen SV, Rietschel E. Questionnaire-based survey of lifetime-prevalence and character of allergic drug reactions in German children. Pediatr Allergy Immunol 2008 Jan 22. Epub ahead.
276. Rebelo Gomes E, Fonseca J, Araujo L, Demoly P. Drug allergy claims in children: From self-reporting to confirmed diagnosis. Clin Exp Allergy 2008; 38: 191-8.
277. Amblard P, Imbert R, Dugois P, Deshors G. Lyell's syndrome with very early onset due to spiramycin. Syndrome de Lyell d'une extrême précocité par spiramycine 1969; 76: 120-1.
278. Handa SP. The Schonlein-Henoch syndrome: Glomerulonephritis following erythromycin. South Med J 1972; 65: 917-20.
279. van Ketel WG. Immediate- and delayed-type allergy to erythromycin. Contact Dermatitis 1976; 2: 363-4.
280. Naik RP, Singh G. Bullous fixed drug eruption presumably due to erythromycin. Dermatologica 1976; 152: 177-80.
281. Cooksley WGE, Powell LW. Erythromycin jaundice: Diagnosis by an in vitro challenge test. Aus N Z J Med 1977; 7: 291-3.
282. Abramov LA, Yust IC, Fierstater EM, Vardinon NE. Acute respiratory distress caused by erythromycin hypersensitivity. Arch Intern Med 1978; 138: 1156-8.
283. Zafrani ES, Ishak KG, Rudzki C. Cholestatic and hepatocellular injury associated with erythromycin esters. Report of nine cases. Dig Dis Sci 1979; 24: 385-96.
284. Paggiaro PL, Loi AM, Toma G. Bronchial asthma and dermatitis due to spiramycin in a chick breeder. Clin Allergy 1979; 9: 571-4.
285. Veien NK, Hattel T, Justesen O, Norholm A. Occupational contact dermatitis due to spiramycin and/or tylosin among farmers. Contact Dermatitis 1980;6:410-3.
286. Lombardi P, Campolmo P, Spallanzani P, Sertoli A. Delayed hypersensitivity to erythromycin. Contact Dermatitis 1982; 8: 416.
287. Keeffe EB, Reis TC, Berland JE. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate. Dig Dis Sci 1982; 27: 701-4
288. Ortun?o JA, Olaso V, Berenguer J. Cholestasis hepatitis caused by erythromycin propionate. Hepatitis colestasica por propionato de eritromicin 1984; 82: 912.
289. Mae Diehl A, Latham P, Boitnott JK. Cholestatic hepatitis from erythromycin ethylsuccinate. Report of two cases. Am J Med 1984; 76: 931-4.
290. Pigatto PD, Riboldi A, Riva F, Altomare GF. Fixed drug eruption to erythromycin. Acta Derm Venereol 1984; 64: 272-3.
291. Moscato G, Naldi L, Candura F. Bronchial asthma due to spiramycin and adipic acid. Clinical Allergy 1984; 14: 355-61.
292. Galland MC, Rodor F, Jouglard J. Spiramycin and allergic toxidermy vasculitis likes. Toxidermie évoquant une vascularite allergique et spiramycine 1987; 42: 227-9.
293. Lund Kofoed M, Oxholm A. Toxic epidermal necrolysis due to erythromycin. Contact Dermatitis 1985; 13: 273.
294. Perrier M, Portier G, de Calan L, Favre JP, Ozoux JP, Rivallain B, et al. Erythromycin-induced hepatitis. Hépatite due à l'érythromycine 1987; 35: 237.
295. Larrey D, Amouyal G, Danan G, Degott C, Pessayre D, Benhamou JP. Prolonged cholestasis after troleandomycin-induced acute hepatitis. J Hepatol 1987;4:327-9.
296. Rigauts HD, Selleslag DL, Van Eyken PL, Van Damme BJ, Fevery JM, Marchal GJ. Erythromycin-induced hepatitis: Simulator of malignancy. Radiology 1988; 169: 661-2.
297. Malo JL, Cartier A. Occupational asthma in workers of a pharmaceutical company processing spiramycin. Thorax 1988; 43: 371-7.
298. Pendleton N, Mallik LJ, Williams JG. Erythromycin rash in glandular fever. Br J Clin Pract 1989; 43: 464-5.
299. Jacqz-Aigrain E, Guillonneau M, Brun P, Broyard A, Bechtel Y. Toxic epidermal necrolysis due to paediatric erythromycin/sulfisoxazole combination. Lancet 1990; 336: 1010-1.
300. Dooms-Goossens A, Bedert R, Degreef H, Vandaele M. Airborne allergic contact dermatitis from kitasamycin and midecamycin. Contact Dermatitis 1990; 23: 118-9.
301. Florido Lopez JF, Lopez Serrano MC, Belchi Hernandez J, Estrada Rodriguez JL. Fixed eruption due to erythromycin. A case report. Allergy 1991; 46: 77-8.
302. Mutalik S. Fixed drug eruption caused by erythromycin. International Journal of Dermatology 1991; 30: 751.
303. Ostlere LS, Langtry JAA, Staughton RCD. Allergy to spiramycin during prophylactic treatment of fetal toxoplasmosis. Br Med J 1991; 302: 970.
304. Shirin H, Schapiro JM, Arber N, Pinkhas J, Sidi Y, Salomon F. Erythromycin base-induced rash and liver function disturbances. Ann Pharmacother 1992; 26: 1522-3.
305. Estrada V, Algarra J, Vargas E, Jimenez De Diego L. Red neck syndrome induced by erythromycin. Sindrome de cuello rojo inducido por eritromicina 1992; 190: 100-1.
306. Malet A, Amat P, Valero A, Bescos M, Merola E, Lluch M. Occupational hypersensitivity to spiramycin. Case report. Hipersesibilidad ocupational a espiramicina a proposito de un caso 1992; 20: 127-30.
307. Sanchez de Dios M, Sanchez Sanchez A, Garcia Ortiz A, Carvajal Garcia-Pando A. [Anaphylactoid Schoenlein-Henoch purpura caused by midecamycin]. Rev Clin Esp 1992; 191: 230-1.
308. De Vega T, Blanco S, Lopez C, Pascual E, Sanchez M, Zamarron A. Clarithromycin-induced leukocytoclastic vasculitis. Eur J Clin Microbiol Infect Dis 1993; 12: 563.
309. Uzzan B, Vassy R, Nicolas P, Chapman A, Perret G. Troleandomycin hepatotoxicity: A case report of overt jaundice and a placebo-controlled trial. Therapie 1993; 48: 61-2.
310. Fernandez Redondo V, Casas L, Taboada M, Toribio J. Systemic contact dermatitis from erythromycin. Contact Dermatitis 1994; 30: 311.
311. Valero Prieto I, Calvo Catala J, Hortelano Martinez E, Abril LdMV, Glez-Cruz Cervellera MI, Herrera Ballester A, et al. [Schoenlein-Henoch purpura associated with spiramycin and with important digestive manifestations]. Rev Esp Enferm Dig 1994; 85: 47-9.
312. Oteo JA, Gomez-Cadinanos RA, Rosel L, Casas JM. Clarithromycin-induced thrombocytopenic purpura. Clin Infect Dis 1994; 19: 1170.
313. Trevisi P, Patrizi A, Neri I, Farina P. Toxic pustuloderma associated with azithromycin. Clin Exp Dermatol 1994; 19: 280-1.
314. Pascual C, Crespo JF, Quiralte J, Lopez C, Wheeler G, Martin-Esteban M. In vitro detection of specific IgE antibodies to erythromycin. J Allergy Clin Immunol 1995; 95: 668-71.
315. Martins C, Freitas JD, Goncalo M, Goncalo S. Allergic contact dermatitis from erythromycin. Contact Dermatitis 1995; 33: 360.
316. Lestico MR, Smith AD. Stevens-Johnson syndrome following erythromycin administration. Am J Health-Syst Pharm 1995; 52: 1805-7.
317. Raymond F, Paillat A, Gambert C, Garnier P. Lyell's syndrome after erythromycin-sulfafurazole and morniflumate administration. Syndrome de Lyelml après administration d'érythromycine-sulfafurazole et de morniflumate 1995;2:494-5.
318. Gomez-Lechon MJ, Carrasquer J, Berenguer J, Castell JV. Evidence of antibodies to erythromycin in serum of a patient following an episode of acute drug-induced hepatitis. Clin Exp Allergy 1996;26:590-6.
319. Jorro G, Morales C, Braso JV, Pelaez A. Anaphylaxis to erythromycin. Ann Allergy Asthma Immunol 1996; 77: 456-8.
320. Valsecchi R, Pansera B, Reseghetti A. Contact allergy to erythromycin. Contact Dermatitis 1996; 34: 428.
321. Vangala R, Cernek PK. Hypersensitivity reaction to clarithromycin [4]. Ann Pharmacother 1996; 30: 300.
322. Perez Moreno JM, Saldana Gonzalez FJ, Puertas Montenegro M, Baez Perea J. [Cholestatic hepatitis caused by midecamycin]. Gastroenterol Hepatol 1996; 19: 459-61.
323. Goossens C, Sass U, Song M. Baboon syndrome. Dermatology 1997; 194: 421-2.
324. Thevenot T, Mathurin P, Martinez F, Moussalli J, Poynard T, Opolon P, et al. Acute hepatitis during hypersensitivity syndrome due to midecamycin. Eur J Gastroenterol Hepatol 1997; 9: 1249- 50.
325. Hubner C, Dietz A, Stremmel W, Stiehl A, Andrassy K. Macrolide-induced Churg-Strauss syndrome in a patient with atopy. Lancet 1997; 350: 563
326. Alvarez-Fernandez JA, Alvarez-Cuesta E, Aragoneses E, Cuevas M. Hypersensitivity to erythromycin: Cross reactivity. J Allergy Clin Immunol 1998; 101: A571.
327. Quinones MD, Sanchez I, Lopez R, Rodriguez F, Martin-Gil D, Jerez J. Pustolosis by erythromycin. Allergy 1998: A274.
328. Acero S, Tabar AI, Echechipia S, Alvarez MJ, Garcia BE. Occupational allergic contact dermatitis due to airborne spiramycin. J Investig Allergol Clin Immunol 1998; 8: 184-5.
329. Alvarez-Fernandez JA, Alvarez-Cuesta E, Aragoneses E, Lizarza S, De La Hoz B, Sanchez-Cano M. Hypersensitivity to macrolides. Allergy 1998: A249.
330. Igea JM, Lazaro M. Hypersensitivity reaction to clarithromycin. Allergy: European Journal of Allergy and Clinical Immunology 1998; 53: 107-9.
331. Rosina P, Chieregato C, Schena D. Fixed drug eruption from clarithromycin. Contact Dermatitis 1998; 38: 105.
332. Gavura SR, Nusinowitz S. Leukocytoclastic vasculitis associated with clarithromycin. Ann Pharmacother 1998; 32: 543-5.
333. Borja JM, Galindo PA, Feo F, Gomez E, Lasanta A. Maculopapular exanthema from diacetyl-midecamycin (MOM). Allergy 1998; 53: 1004-5.
334. Kruppa A, Scharffetter-Kochanek K, Krieg T, Hunzelmann N. Immediate reaction to roxithromycin and prick test cross-sensitization to erythromycin and clarithromycin. Dermatology 1998; 196: 335-6.
335. Barbaud A, Reichert-Penetrat S, Trechot P, Jacquin-Petit MA, Ehlinger A, Noirez V, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 1998; 139: 49-58.
336. Horn S, Aglas F, Horina JH. Cholestasis and liver cell damage due to hypersensitivity to erythromycin stearate - Recurrence following therapy with erythromycin succinate. Wiener Klinische Wochenschrift 1999; 111: 76-7.
337. Gallardo MA, Thomas I. Hypersensitivity reaction to erythromycin. Cutis 1999;64:375-6.
338. Goldberg EI, Shoji T, Sapadin AN. Henoch-Schonlein purpura induced by clarithromycin. Intern J Dermatol 1999; 38: 706-8.
339. Williams DA. Stevens-Johnson syndrome after erythromycin therapy while deployed at sea. Milit Med 2000; 165: 636-7.
340. Schissel DJ, Singer D, David-Bajar K. Azithromycin eruption in infectious mononucleosis: A proposed mechanism of interaction. Cutis 2000; 65: 163-6.
341. Hamamoto Y, Ohmura A, Kinoshita E, Muto M. Fixed drug eruption due to clarithromycin. Clin Exp Dermatol 2001; 26: 48-9.
342. Gangemi S, Ricciardi L, Fedele R, Isola S, Purello-D'Ambrosio F. Immediate reaction to clarithromycin. Allergol Immunopathol 2001; 29: 31-2.
343. Cascaval RI, Lancaster DJ. Hypersensitivity syndrome associated with azithromycin. Am J Med 2001; 110: 330-1.
344. San Pedro de Saenz B, Gomez A, Quiralte J, Florido JF, Martin E, Hinojosa B. FDE to macrolides. Allergy 2002; 57: 55-6.
345. Masia M, Gutierrez F, Jimeno A, Navarro A, Borras J, Matarredona J, et al. Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clarithromycin administration in an alcoholic patient receiving disulfiram therapy. Arch InternMed 2002; 162: 474-6.
346. Dakdouki GK, Obeid KH, Kanj SS. Azithromycin-induced rash in infectious mononucleosis. Scand J Infect Dis 2002; 34: 939-41.
347. Gurvinder SK, Tham P, Kanwar AJ. Roxithromycin induced acute urticaria. Allergy 2002; 57: 262.
348. Amichai B, Grunwald MH. 'Baboon syndrome' following oral roxithromycin. Clin Exp Dermatol 2002; 27: 523.
349. Terzano C, Petroianni A. Lesson of the week: Clarithromycin and pulmonary infiltration with eosinophilia. Br Med J 2003; 326: 1377-8.
350. Borras-Blasco J, Enriquez R, Amoros F, Cabezuelo JB, Navarro-Ruiz A, Perez M, et al. Henoch-Schönlein purpura associated with clarithromycin. Int J Clin Pharmacol Ther 2003; 41: 213-6.
351. Freymond N, Catelain A, Cousin F, Nicolas JF. Skin delayed-type hypersensitivity to josamycin. Allergy 2003; 58: 1319-20.
352. Baz K, Ikizoglu G, Yazici AC, Kokturk A, Tiftik N, Apa DD, et al. Fatal aplastic anaemia in a patient with clarithromycin-induced toxic epidermal necrolysis. J Eur Acad Dermatol Venereol 2004; 18: 104-5.
353. Mimesh S, Pratt M. Occupational airborne allergic contact dermatitis from azithromycin. Contact Dermatitis 2004; 51: 151.
354. Martinez Alonso JC, Callejo Melgosa A, Fuentes Gonzalo MJ, Martin Garcia C. Fixed drug eruption on the tongue due to clarithromycin. Contact Dermatitis 2005; 53: 121-2.
355. Khaldi N, Miras A, Gromb S. Toxic epidermal necrolysis and clarithromycin. Can J Clin Pharmacol 2005; 12: E264-e8.
356. Schmutz JL, Barbaud A, Trechot P. Azithromycin and Stevens-Johnson syndrome. Azithromycine et syndrome de Stevens-Johnson. Ann Dermatol Venereol 2005; 132: 728.
357. Zink A, Erni S, Fliegner M. Antibiotics, purpura and ulcera: A case of leucocytoclastic vasculitis after clarithromycin. Antibiotika, purpura und ulzera: Eine leukozytoklastische vaskulitis nach clarithromycin. Dtsch Med Wochenschr 2006; 131: 2217-20.
358. Brkljacic N, Gracin S, Prkacin I, Sabljar-Matovinovic M, Mrzljak A, Nemet Z. Stevens-Johnson Syndrome as an unusual adverse effect of azithromycin. Acta Dermatovenerologica Croatica 2006; 14: 40-5.
359. Chew GYJ, Hawkins CA, Cherian M, Hurwitz M. Roxithromycin induced hypersensitivity pneumonitis. Pathology 2006; 38: 475-7.
360. Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum Iii PP, Banks PM. Brief communication: Severe hepatotoxicity of telithromycin: Three case reports and literature review. Ann Intern Med 2006; 144: 415-20.
361. Sanchez-Morillas L, Laguna-Martinez JJ, Reano-Martos M, Rojo-Andres E, Gomez-Tembleque P, Santaolalla-Montoya M. Hypersensitivity to spiramycin with good tolerance of other macrolides. J Invest Allergol Clin Immunol 2007; 17: 417-8.
362. Dellestable P, Weber-Muller F, Trechot P, Vernassiere C, Schmutz JL, Barbaud A. Co-sensitization to drugs belonging to different chemical classes during the same episode of cutaneous adverse drug reaction: Two cases. Deux médicaments de même imputabilité dans une toxidermie (deux cas): Limite des tests épicutanés. Ann Dermatol Venereol 2007; 134: 655-8.
363. Milkovic-Kraus S, Macan J, Kanceljak-Macan B. Occupational allergic contact dermatitis from azithromycin in pharmaceutical workers: A case series. Contact Dermatitis 2007; 56: 99-102.
364. Bottenberg MM, Wall GC, Hicklin GA. Apparent anaphylactoid reaction after treatment with a single dose of telithromycin. Ann Allergy Asthma Immunol 2007; 98: 89-91.
365. Bedard MS, Gilbert M. Telithromycin-induced TEN: Report of a case. Arch Dermatol 2007; 143: 427-8.
366. Fylaktakidou KC, Hadjipavlou-Litina DJ, Litinas KE, Varella EA, Nicolaides DN. Recent developments in the chemistry and in the biological applications of amidoximes. Curr Pharm Des 2008; 14(10): 1001-47.
367. Giovannetti A, Pierdominici M, Di Iorio A, Cianci R, Murdaca G, Puppo F, et al. Apoptosis in the homeostasis of the immune system and in human immune mediated diseases. Curr Pharm Des 2008; 14(3): 253-68.
368. Isolauri E, Kalliomaki M, Laitinen K, Salminen S. Modulation of the maturing gut barrier and microbiota: A novel target in allergic disease. Curr Pharm Des 2008; 14(14): 1368-75.